Faes Farma, S.a. · BME:FAE
Faes Farma — Investor Day (March 2023)
38 slides from Faes Farma's investor day presentation, Mar 29, 2023
Slide 1: Caring for Today and Tomorrow – Capital Markets Day
Caring for Today and Tomorrow Capital Markets Day 29th of March 2023
Slide 2: Index
1// 3// Our strategic 2022 results pillars and 2023 commitments Index 2// 4// Our R&D Closing and Q&A innovation strategy FAES FARMA/Caring for Today and Tomorrow 2
Slide 3: Index
1// 3// Our strategic 2022 results pillars and 2023 commitments Index 2// 4// Our R&D Closing and Q&A innovation strategy FAES FARMA/Caring for Today and Tomorrow 3
Slide 4: Faes Farma today
Faes Farma today Direct presence Iberia+subsidiaries Presence of Faes products via partners and exports Diversification ~400M€ ~60M€ PHARMA INCOME N&AH INCOME Profitability ~120M€ EBITDA +6% vs. 2021 Geographic footprint PRESENCE IN >130 COUNTRIES Employment ~1.800 Employees FAES FARMA/Caring for To
Slide 5: Our strategic pillars
1// Growing STRATEGIC PRODUCT lines Our strategic 2// Enhancing the value of our pillars DIRECT SALES MODEL 3// Focus on OPERATIONAL EXCELLENCE FAES FARMA/Caring for Today and Tomorrow 5
Slide 6: Strategic product lines
Strategic product lines STRATEGIC PRODUCTS Pillar I. Growth around our strategic product lines through internationalisation via licences Bilastine Calcifediol Mesalazine Products “tier2” Leading global Improved efficacy in the Treatment for ulcerative Other products completing antihistamine, with gr
Slide 7: Bilastine: a leading antihistamine
Strategic product lines STRATEGIC PRODUCTS Bilastine. A leading antihistamine that will continue to maintain its important value in the coming years... Total income Double-digit growth in relevant markets in Asia Pacific, Canada and 2022 LATAM, and high single digits in Europe. 110M€ (+16% vs. 2021)
Slide 8: Bilastine: leading position in major global markets
Strategic product lines STRATEGIC PRODUCTS Bilastine. … With a leading position in major global markets and growth potential remaining in key markets Top antihistamine markets for Faes Farma and presence of Bilastine [R6A, 2022, M€] Japan 18% 688 M€ BILASTINE 1 Bilastine growth +9% in volume / +1% i
Slide 9: Calcifediol will continue to sustain strong growth
Strategic product lines STRATEGIC PRODUCTS Calcifediol will continue to sustain strong growth in the future … Calcifediol will continue to grow in current and newly launched markets Total income 2022 Growth in our main markets (Spain, Italy, Portugal) 45M€ Global Vitamin D market DIRECT SALES >1.800
Slide 10: Calcifediol: prospects for growth in new markets
Strategic product lines STRATEGIC PRODUCTS Calcifediol. … With ample prospects for growth in new markets globally Top Faes Farma Vitamin D markets and presence of Calcifediol[2022, M€] Brazil 18% 259 M€ Dossier submission 2022 Italy 2,6% 5% 195 M€ Average annual growth from 2020 of c.25% in value Ge
Slide 11: Mesalazine: basic treatment for ulcerative colitis
Strategic product lines STRATEGIC PRODUCTS Mesalazine. Basic treatment for mild-moderate ulcerative colitis, with multiple planned launches Mesalazine will continue to be developed in order to have the widest range of formulations for the molecule Total income 2022 15M€ Global Mesalazine Market Deve
Slide 12: Pending growth in strategic products' markets
Strategic product lines STRATEGIC PRODUCTS Pending growth. Our strategic products are yet to be launched in markets worth more than €1.6 billion. Bilastine Calcifediol Mesalazine Market size of Current market current sales presence Faes ~2.870M€ ~600M€ ~370M€ ~3.840M€ Farma DIRECT SALES Size of mark
Slide 13: Enhancement and development of our direct sales model
PRODUCTOS ESTRATÉGICOS Direct sales model Pillar II. Enhancement and development of our direct sales model Pharma Iberia … an established, flexible and resilient business, with a Faes LATAM proven portfolio renewal capability … replicating Faes Farma's business model in Spain, with a presence in six
Slide 14: Pharma Iberia contributes nearly 50% of pharma turnover
PRODUCTOS ESTRATÉGICOS Pharma Iberia Direct sales model Our Pharma Iberia business contributes nearly 50% of the Group's pharma division's turnover... Prescription A consolidated business with a with a portfolio of proprietary and licensed prescription products that are leaders in high contribution
Slide 15: Pharma Iberia portfolio renewal and resilience
PRODUCTOS ESTRATÉGICOS Pharma Iberia Direct sales model … and has demonstrated its ability to renew its portfolio and overcome the challenges that have marked recent years Proven resilience and portfolio renewability Business model: Successful redefinition and Total revenues Pharma Spain [Prescripti
Slide 16: Continuing to grow Faes LATAM
PRODUCTOS ESTRATÉGICOS Pharma LATAM Direct sales model We will continue to grow Faes LATAM, our direct sales platform in Latin America. … x2 times revenue figure Presence in six major Latin in the last five years American markets Presence in Central America, x6 times EBITDA figure Colombia, Chile, M
Slide 17: Ambition to become a Top 25 laboratory in LATAM
PRODUCTOS ESTRATÉGICOS Pharma LATAM Direct sales model … with the ambition to become one of the Top 25 laboratories in the main markets Target Be one of the Top 25 labs in most of our geographies and continue to increase relative EBITDA to 20% by 2025. 2025 Evolution of total revenues of Faes LATAM
Slide 18: Developing Faes OMA
PRODUCTOS ESTRATÉGICOS Pharma OMA Direct sales model In parallel, we will continue to develop Faes OMA, adding new markets and growing in existing markets More than 8 million units sold in the Direct presence Middle East and Africa region Presence via partners Medium-term target markets 21M€ >50 >40
Slide 19: Strengthening our focus on operational excellence
Operational Excellence STRATEGIC PRODUCTS Pillar III. In a complex macroeconomic environment, we are strengthening our focus on operational excellence Relevance of the pharmaceutical industry as Pressure on margins in the pharmaceutical In a complex a strategic sector for Spain and the EU sector, du
Slide 20: New Industrial Plan enhances production capabilities
Industrial Plan Operational Excellence STRATEGIC PRODUCTS The new Industrial Plan will enhance our production capabilities and enable the growth plans Macro and sectoral context Key objectives of the Industrial Plan Increasing industrial capacity Relevance of the pharmaceutical industry as − x3 indu
Slide 21: Work on the new Derio plant continues on schedule
Industrial Plan Operational Excellence STRATEGIC PRODUCTS Work on the new Derio plant continues on schedule with the planned schedule DIRECT SALES OPERATIONAL EXCELLENCE FAES FARMA/Caring for Today and Tomorrow 21
Slide 22: Operational Efficiency Plan
Operational Efficiency Plan Operational Excellence STRATEGIC PRODUCTS At the same time, we are developing a plan focused on improving our operational efficiency Macro and sectoral context Key objectives of the Operational Efficiency Plan Pressure on margins in the pharmaceutical Optimisation of our
Slide 23: Our R&D and innovation strategy
1// Our strategic pillars 2// Our R&D and innovation strategy 2// 4// Our R&D Closing and and Q&A innovation strategy FAES FARMA/Caring for Today and Tomorrow 23
Slide 24: Strengthening and optimising our R&D&I department
Reinforcement and optimisation of R&D&I Strengthening and optimising our R&D&I department: prioritising value generation for the future Key new recruits to reinforce the Flexibility: efficiency, agility and x1.8 dedicated resources vs. 2017 R&D&I team external collaboration Progressive increase of i
Slide 25: R&D&I focuses on four therapeutic areas
Therapeutic areas R&D&I focuses on four therapeutic areas with high growth potential Allergic diseases Gastrointestinal Bone Immunomodulation Pain Allergic rinitis Ulcerative colitis Vitamin D deficiency Painful muscle spasms Target Allergic rhinoconjunctivitis Eosinophilic oesophagitis Osteoporosis
Slide 26: Promising research pipeline
Research pipeline Promising research pipeline: we continue to advance our key projects and introduce early-stage projects… Therapeutic area Project Innovation pipeline stage Next key milestone - in progress 1 Early discovery 2 Screening 3 Optimisation 4 Pre-regulatory FAE4URT Allergic diseases FAE6R
Slide 27: Solid innovation pipeline
Innovation pipeline Solid innovation pipeline: we continue to develop our product ranges in our target indications Therapeutic area Project Innovation pipeline stage Pharmaceutical Clinical phases Registration Next key milestone - in progress development Phase I Phase II Phase III Launch Q2 Bilastin
Slide 28: Results 2022 and commitments 2023
1// 3// Our strategic Results 2022 pillars and 3// commitments Results 2022 2023 and commitments 2// 4// 2023 Our R&D Closing and and Q&A innovation strategy FAES FARMA/Caring for Today and Tomorrow 28
Slide 29: We have met our financial objectives for 2022
We have met our financial objectives for 2022 … Guidance 2022 Results 2022 2022E: 422M€ - 437M€ Net Sales Growth of ~8% vs. 2021 (399M€) 439M€ +10,1% PBT Profit before Tax 2022E: 100M€ - 104M€ Growth of ~10% vs. 2021 (94M€) 101M€ +9,1% 2022E: 89M€ - 93M€ NP Net Profit Growth of ~11% vs. 2021 (83M€)
Slide 30: Eleven years of profitable growth
… marking eleven years of profitable growth in our business Total income Profit Before Tax Evolution 2011-2022 Evolution 2011-2022 x2,4 x8,5 +8% CAGR +21% CAGR 462M€ 101M€ 2011 2022 2011 2022 FAES FARMA/Caring for Today and Tomorrow 30
Slide 31: 2022 growth fuelled by strategic product lines
In 2022, growth was fueled by our key growth engines: our strategic products lines and international business Revenue performance: portfolio perspective Revenue performance: business area perspective ▲19M€ ▲33M€ Growth of International business strategic growth products 462M€ 462M€ (1M€) 1M€ (1M€) 1
Slide 32: Animal Health & Nutrition maintained business in 2022
Animal Health & Nutrition´s (NySA) has maintained its business in 2022 despite the challenging industry context. Outlook to return to growth in 2023 In 2022, the NySA business has … despite this backdrop, NySA has … with an outlook to get back to faced a complex macro and sectoral managed to sustain
Slide 33: Outlook 2023
Outlook 2023. In 2023, our business will continue to grow, but we are facing relevant impacts to our P&L Business Impacts 2023 Faes LATAM Growth:▲~20% in income and EBITDA Stabilization of the Animal Health and Nutrition business Total Income Growth of ~5,5% vs. 2022 Growth of the respiratory franch
Slide 34: ESG key figures and milestones 2022
1// Environment Eco-efficiency and sustainability in the ▼ 10% Water ▼ 48% carbon footprint construction of our new pharmaceutical production consumption in scope 2 in 2022 plant in Derio: LEED 2022 certification 2// Social We continue to strengthen our commitment to the integration of ESG into our
Slide 35: Balancing resource allocation between growth and shareholder return
Balancing resource allocation between growth and shareholder return We continue to invest to drive …and priortize the return for our business growth... shareholders Incre resources related to R&D&I : product 2023 Dividend: 55% theoretical pay out, above the market development and infrastructure aver
Slide 36: Closing and Q&A
1// Our strategic pillars 4// Closing and Q&A 2// 4// Our R&D Closing and and Q&A innovation strategy
Slide 37: Faes Farma
AF FAES FARMA
Slide 38: Disclaimer
Disclaimer This presentation has been prepared and published by Faes Farma Group and is presented for informational purposes only. This presentation is not a brochure, nor is it an offer or recommendation to make an investment. This presentation does not imply any subscription commitment, nor an off